feed,title,long_url,short_url
Benzinga,Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings,https://benzinga.com/general/biotech/22/11/29767727/takedas-approved-blood-cancer-drug-hits-primary-goal-in-newly-diagnosed-patient-settings,https://bit.ly/3V4rBQv
Benzinga,Alibaba Q2 Earnings: Clocks Only 3% Revenue Growth As Economic Slowdown And Regulatory Headwinds Weigh; Approves Additional $15B Buyback,https://benzinga.com/news/earnings/22/11/29764002/alibaba-q2-earnings-clocks-only-3-revenue-growth-as-economic-slowdown-and-regulatory-headwinds-weig,https://bit.ly/3EeGoBj
